Original InvestigationClinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
The ARISTOTLE study was funded by Bristol-Myers Squibb and Pfizer. Dr. Zeitouni has received research grants from the Federation Française de Cardiologie and Institut Servier; and has received consulting fees from Bristol-Myers Squibb and Pfizer. Dr. Lopes has received research grants from Bristol-Myers Squibb, Pfizer, Amgen, GlaxoSmithKline, Medtronic PLC, Sanofi, and Merck; and has received consulting fees from Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Bayer AG, Daiichi-Sankyo, and Portola. Dr. Christersson has received lecture fees from Bristol-Myers Squibb and Bayer; and has served on the Advisory Board of Boehringer Ingelheim and Novartis. Dr. Siegbahn has received institutional research grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Roche Diagnostics; and has received consulting fees from Olink Proteomics. Dr. De Caterina has received fees, honoraria, and research funding from Sanofi, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, Novartis, Merck, and Portola; and has served as a consultant for Roche. Dr. Steg has received research grants from Amarin, Bayer, Sanofi, and Servier; and has received speaking/consulting fees from Amarin, Amgen, AstraZeneca, Bayer/Janssen, Boehringer Ingelheim, Bristol-Myers Squibb, Idorsia, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, and Servier. Dr. Granger has received research grants from Akros, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, Pfizer, Armetheon, AstraZeneca, U.S. Food and Drug Administration, GlaxoSmithKline, The Medicines Company, Medtronic Foundation, Medtronic Inc., and Novartis; and has received consulting fees from Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Celecor, Correvio, Daiichi-Sankyo, Espero, Janssen, Pfizer, Abbvie, Armetheon, AstraZeneca, Eli Lilly, Gilead, GlaxoSmithKline, Hoffmann-La Roche, The Medicines Company, National Institutes of Health, Novartis, Sirtex, Verseon, Apple, Medscape, Merck, Novo Nordisk, Roche Diagnostics, Rhoshan, and Rho Pharmaceuticals. Dr. Wallentin has received institutional research grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Roche Diagnostics, and Merck & Co; has received consulting fees from Abbott; and has 2 patents for GDF-15 with Roche Diagnostics (EP2047275B1 and US8951742B2). Dr. Alexander has received research grants from Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, CryoLife, CSL Behring, U.S. Food and Drug Administration, National Institutes of Health, Sanofi, and VoluMetrix; and has received consulting fees from Pfizer, Bristol-Myers Squibb, AbbVie Pharmaceuticals, CSL Behring, Novo Nordisk, Portola Pharmaceuticals, Quantum Genomics, Teikoku Pharmaceuticals, VA Cooperative Studies, and Zafgen. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.